Compare Cassava Sciences Inc (FLNA) vs STMicroelectronics NV (STM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs STMicroelectronics NV — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while STMicroelectronics NV trades at $53.69 (market cap $50.29B). The key difference: STMicroelectronics NV is far larger — about 1276.4× Cassava Sciences Inc's market cap, and STMicroelectronics NV pays a 0.64% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and STMicroelectronics NV for 66 Days on average.
| FLNA | STM | |
|---|---|---|
Market Cap | $39.40M | $50.29B |
Volume | 759,018 | 9,536,788 |
Sector | Health | Technology |
52-Week High | $4.64 | $79.91 |
52-Week Low | $0.68 | $21.20 |
Typical Hold Time | 37 Days | 66 Days |
Enterprise Value | -$43.28M | $47.81B |
Dividend Yield | — | 0.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8136, down 7.01% today, with a bearish technical signal from moving averages. The company shows negative profitability with ROE at -55.79% and ROA at -35.34%, though it has beaten EPS estimates for three consecutive quarters. Recent FDA approval to lift the clinical hold on simufilam for epilepsy research provides a positive catalyst, with patient screening expected by Q1 2027.
Despite operational losses and negative cash flow, analyst consensus is bullish with 8 buy ratings versus 4 hold. The key investment opportunity lies in the clinical progress of simufilam, while risks include sustained cash burn and reliance on successful drug development outcomes in a competitive biotech landscape.
STM trades at $56.18, down 4.33% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish technical signal with support near $56, but faces headwinds from recent earnings misses and negative net income margins. Revenue has declined from $17.3B in 2023 to $11.8B in 2025, though AI data-center growth offers a potential catalyst, with the company targeting over $2B in AI revenue by 2027 according to Reuters on 2026-09-09.
The outlook is cautiously optimistic, driven by analyst consensus favoring a Buy rating and a $77.31 price target, implying significant upside. However, risks include volatile profitability, high P/E of 101.89, and dependence on cyclical semiconductor demand. Near-term performance hinges on Q3 2026 earnings versus the $0.40 EPS expectation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →
